European Psychiatry - Volume 33 - March 2016

774 / 812

S770 24th European Congress of Psychiatry / European Psychiatry 33S (2016) S349–S805
EV1321
Therapeutic attitudes and clinical
global impression: A 2-year follow-up
study of 33 outpatients with a mental
disorder in treatment with
paliperidone palmitate
M.D. Perez Lopez ∗, M. Soto laguna , J. Prados Gomez ,
I. Zarranz Herrera Oria , R. Perez Asenjo , S. Bola˜no Mendoza ,
M. Fernandez Torrija Daza , P. Gonzalez Rivera ,
B. Herrejon Teodoro
Hospital Provincial de Toledo, Psiquiatria, Toledo, Spain
∗ Corresponding author.
Introduction Maintaining antipsychotic therapy in mental dis-
order is important in preventing relapse, rehospitalization, and
suicide. Lack of awareness of illness may be a leading cause for non-
adherence. Long-acting depot can prevent non- adherence and thus
potentially contribute to better patient outcomes.
Objective The aim of this prospective, observational, non
interventional 2-year-long study is to assess severity and post-
intervention changes and attitudes toward medication of a group
of patients treated paliperidone palmitate (PP).
Methods Thirty-three outpatients stabilised with PP during the
last 24 months. Inclusion criteria were: patients’ age (> 18 years),
a diagnosis of schizophrenia, bipolar disorder, schizoaffective dis-
order stabilised during the last 12 months with PP, without a
diagnostics from axis I or II (except for nicotine of caffeine)
and able to sign the inform consent. Data collected: general
sociodemographic and clinical data (age, sex, level of education,
socioeconomic situation, family support, psychiatric diagnosis,
years of evolution, use/abuse of substances, treatment, previous
and later number of hospitalisations. Evaluations included disease
severity (Clinical Global Impression-Severity (CGI-S) and Drug Atti-
tude Inventory, (DAI)).
Results Thirty-threeoutpatientswere followed during 24months
[mean dose 132,58 (44,4) mg], 75,8% were men, age 45,05 years
old, 87,8% with a diagnoses of paranoid schizophrenia. Antipsy-
chotic monotherapy increased over the time with PP. Significant
improvements were observed on both Clinical Global Impression
and Drug Attitude Inventory. The number of rehospitalizations and
mean stays decreased from the beginning until the end of these 24
months.
Conclusions Our results suggest an improvement in the patient’s
clinical vision and attitude towards medication with long-acting
depot.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1322
DECIDE Study: Effectiveness of shared
decision-making in treatment
planning at discharge of inpatient
with schizophrenia. Experience after
20 months of the study
J. Pérez Revuelta ∗, J.M. Pascual Pa˜no , I. Lara Ruiz-Granados ,
F. Gonzalez Saiz , C. Rodriguez Gomez , J.M. Mongil San Juan ,
M. Ayerbe de Celis , M. Pavon Garcia , J. Mestre Morales ,
M.J. Garcia del Rio , R. Guerrero Vida , J.M. Villagran Moreno
1 Servicio Andaluz Salud, Fundacion Biomedica Cadiz, Clinical
Management Unit of Mental Health, Jerez de la Frontera, Spain
2 Servicio Andaluz Salud, Clinical Management Unit of Mental Health,
Jerez de la Frontera, Spain
3 Servicio Andaluz Salud, Macarena Clinical Management Unit of
Mental Health, Sevilla, Spain
∗ Corresponding author.
Introduction Shared decision-making denotes a structured pro-
cess that encourages full participation by patient and provider
in making complex medical decisions. There has been extensive
and growing interest in its application to long-term illnesses but
surprisingly not in severe psychiatric disorders, such as schizophre-
nia. However, the great majority of schizophrenics are capable of
understanding treatment choices and making rational decisions.
Although the main justification for shared decision-making is ethi-
cal, several randomized controlled trials support its effectiveness in
improving the quality of decisions, but robust evidence in objective
health outcomes is needed.
Aims and objectives Of the study: to demonstrate the effective-
ness, measured as treatment adherence and readmissions at 3, 6
and 12 months, of shared decision making in the choice of antipsy-
chotic treatment at discharge.
Of the oral presentation: to present the study design; to make an
interim report of the data obtained at the moment of the congress.
Methods Randomized controlled trial, prospective, two parallel
groups, not masked, comparing two interventions (shared deci-
sion making and treatment as usual). Study population: Inpatients
diagnosed of schizophrenia and schizoaffective disorders (ICD-
10/DSM-IV-R: F20 y F25) at Adult Acute Hospitalization Unit at
Jerez General Hospital.
Results Currently in the recruiting phase with 55 patients
included in the study. An interim analysis of at least half of the
target sample size.
Conclusions We will show the study design and decision tools
employed. Conclusions in relation to the effectiveness (adherence
and readmissions) and subjective perception.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EV1323
DECIDE Study: Antipsychotic
treatment profile. Comparison of
antipsychotic polytherapy in patients
discharged after acute episode of
UHSM, taking decisions shared vs.
usual care strategies
J. Pérez Revuelta ∗, M. Ayerbe de Celis , J.M. Mongil San Juan ,
C. Rodriguez Gomez , J.M. Villagran Moreno
1 San Fernando, Spain
2 Servicio Andaluz Salud, Clinical Management Unit of Mental Health,
Jerez de la Frontera, Spain
∗ Corresponding author.
Introduction Shared decision-making denotes a structured pro-
cess that encourages full participation by patient and provider
in making complex medical decisions. Although the main justifi-
cation for shared decision-making is ethical, several randomized
controlled trials support its effectiveness in improving the quality
of decisions, but robust evidence in objective health outcomes is
needed.
Aims Analyze the degree of antipsychotic politherapy or
monotherapy in patients discharged after their inclusion in the
study and randomized to Share Decision-Making or Treat as Usual.
Present preliminary conclusions after 20 months of follow-up.
Methods Randomized controlled trial, prospective, two parallel
groups, not masked, comparing two interventions (shared decision
making and treatment as usual). Previous antipsychotic treatment
is collected by interviewing patient and family and as included in
digital history and health card, discharge and reviews conducted at
3, 6 and 12 months.
Results Interim analysis shows there are no differences between
groups (SDM and TaU) before intervention, we note the following
results: